|
WO2021058480A1
|
|
Needle assembly with retractable biostatic plug
|
|
DK202001007A1
|
|
Dose sensor with means for measuring during mcu wake-up
|
|
WO2021043971A1
|
|
Method and equipment for fractionation of granules for use in pharmaceutical compositions
|
|
WO2021043803A1
|
|
Process for producing a tablet comprising glp-1 peptides
|
|
WO2021069142A1
|
|
Dose sensing module with friction enhancing means
|
|
WO2021037650A1
|
|
Skin-mountable combined drug delivery port device
|
|
WO2021037653A1
|
|
Infusion port with pairing functionality
|
|
WO2021023855A1
|
|
Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
|
WO2021023811A1
|
|
Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
|
WO2021023817A1
|
|
Solid composition comprising a pyy compound and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
|
JP2020172543A
|
|
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
|
|
WO2021013907A1
|
|
Capsule device having improved self-righting ability
|
|
WO2021009027A1
|
|
High concentration insulin formulation
|
|
WO2021004864A1
|
|
Generation of neural stem cell lines derived from human pluripotent stem cells
|
|
WO2020260563A1
|
|
Safe immuno-stealth cells
|
|
WO2020260576A1
|
|
Drug delivery device with plunger rod having nonuniform stopper interface
|
|
WO2020245448A1
|
|
Ingestible device with delivery member detachment
|
|
WO2020245409A1
|
|
Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof
|
|
WO2020245295A1
|
|
Dual chamber drug reservoir and stopper therefor
|
|
WO2020229628A1
|
|
Methods for obtaining eye field progenitor cells from human pluripotent stem cells
|
